Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients

Else A. Aalbersberg, Daphne M.V. Huizing, Iris Walraven, Berlinda J. de Wit-van der Veen, Harshad R. Kulkarni, Aviral Singh, Marcel P.M. Stokkel and Richard P. Baum
Journal of Nuclear Medicine September 2019, 60 (9) 1259-1265; DOI: https://doi.org/10.2967/jnumed.118.224386
Else A. Aalbersberg
1Department of Nuclear Medicine, ENETS Centre of Excellence, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daphne M.V. Huizing
1Department of Nuclear Medicine, ENETS Centre of Excellence, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iris Walraven
2Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berlinda J. de Wit-van der Veen
1Department of Nuclear Medicine, ENETS Centre of Excellence, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harshad R. Kulkarni
3Theranostics Centre for Molecular Radiotherapy and Precision Oncology, ENETS Centre of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aviral Singh
3Theranostics Centre for Molecular Radiotherapy and Precision Oncology, ENETS Centre of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; and
4GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel P.M. Stokkel
1Department of Nuclear Medicine, ENETS Centre of Excellence, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard P. Baum
3Theranostics Centre for Molecular Radiotherapy and Precision Oncology, ENETS Centre of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 60 no. 9 1259-1265
DOI 
https://doi.org/10.2967/jnumed.118.224386
PubMed 
30850483

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication December 12, 2018
  • Accepted for publication February 6, 2019
  • Published online September 3, 2019.

Article Versions

  • previous version (March 8, 2019 - 13:06).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Else A. Aalbersberg*,1,
  2. Daphne M.V. Huizing*,1,
  3. Iris Walraven2,
  4. Berlinda J. de Wit-van der Veen1,
  5. Harshad R. Kulkarni3,
  6. Aviral Singh3,4,
  7. Marcel P.M. Stokkel†,1 and
  8. Richard P. Baum†,3
  1. 1Department of Nuclear Medicine, ENETS Centre of Excellence, Netherlands Cancer Institute, Amsterdam, The Netherlands
  2. 2Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  3. 3Theranostics Centre for Molecular Radiotherapy and Precision Oncology, ENETS Centre of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; and
  4. 4GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
  1. For correspondence or reprints contact: Else A. Aalbersberg, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. E-mail: e.aalbersberg{at}nki.nl
  1. ↵* Contributed equally to this work.

  2. ↵† Contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 29 Citations
  • 29 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
    Jingjing Zhang, Qingxing Liu, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni, Richard P. Baum
    Journal of Nuclear Medicine 2020 61 11
  • Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
    David L. Chan, Aimee R. Hayes, Ioannis Karfis, Alice Conner, Luke Furtado O’Mahony, Magdalena Mileva, Elizabeth Bernard, Paul Roach, Gwennaëlle Marin, Nick Pavlakis, Geoffrey Schembri, Gopinath Gnanasegaran, Clementine Marin, Bruno Vanderlinden, Shaunak Navalkissoor, Martyn E. Caplin, Patrick Flamen, Christos Toumpanakis, Dale L. Bailey
    British Journal of Cancer 2023 128 4
  • Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
    Valentina Ambrosini, Lucia Zanoni, Angelina Filice, Giuseppe Lamberti, Giulia Argalia, Emilia Fortunati, Davide Campana, Annibale Versari, Stefano Fanti
    Cancers 2022 14 4
  • The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
    Aimee R. Hayes, Luke Furtado O'Mahony, Ann-Marie Quigley, Gopinath Gnanasegaran, Martyn E. Caplin, Shaunak Navalkissoor, Christos Toumpanakis
    Clinical Nuclear Medicine 2022 47 1
  • Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting
    Keerti Sitani, Rahul V Parghane, Sanjay Talole, Sandip Basu
    The British Journal of Radiology 2021 94 1117
  • Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors
    Swayamjeet Satapathy, Bhagwant Rai Mittal, Ashwani Sood, Apurva Sood, Rakesh Kapoor, Rajesh Gupta
    Clinical Nuclear Medicine 2020 45 9
  • PRRT: identikit of the perfect patient
    M. Albertelli, A. Dotto, C. Di Dato, P. Malandrino, R. Modica, A. Versari, A. Colao, D. Ferone, A. Faggiano
    Reviews in Endocrine and Metabolic Disorders 2021 22 3
  • Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
    Luca Urso, Stefano Panareo, Angelo Castello, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Matteo Caracciolo, Eugenia Tonini, Giorgia Valpiani, Alessandra Boschi, Licia Uccelli, Corrado Cittanti, Mirco Bartolomei
    Pharmaceutics 2022 14 10
  • Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu‐octreotate peptide radionuclide therapy
    Kim R. Kennedy, John Harvey Turner, William B. G. MacDonald, Phillip G. Claringbold, Glenn Boardman, David T. Ransom
    Cancer 2022 128 11
  • The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
    Tristan Ruhwedel, Julian M. M. Rogasch, Kai Huang, Henning Jann, Imke Schatka, Christian Furth, Holger Amthauer, Christoph Wetz
    Cancers 2021 13 4

Article usage

Article usage: March 2019 to April 2025

AbstractFullPdf
Mar 2019303034
Apr 2019115017
May 201991020
Jun 20195208
Jul 201982015
Aug 20197008
Sep 20198241379
Oct 20192161389
Nov 2019140617
Dec 20198038
Jan 20209248
Feb 20204411
Mar 2020601313
Apr 2020672013
May 2020663522
Jun 2020381912
Jul 202050129
Aug 202021378
Sep 202038148
Oct 2020361917
Nov 2020262518
Dec 2020243431
Jan 2021192723
Feb 2021134022
Mar 2021182727
Apr 202193125
May 202193116
Jun 2021164121
Jul 202163224
Aug 202161819
Sep 202192415
Oct 2021133625
Nov 2021263734
Dec 2021124818
Jan 2022241119
Feb 2022182611
Mar 202274113
Apr 20226487
May 202285411
Jun 202263121
Jul 202243813
Aug 20225208
Sep 202253425
Oct 202252310
Nov 202231715
Dec 20224309
Jan 2023171819
Feb 202342212
Mar 20238269
Apr 202351915
May 202362721
Jun 202332314
Jul 20237159
Aug 2023112516
Sep 20237387
Oct 202384217
Nov 202373425
Dec 202333716
Jan 202473418
Feb 202433218
Mar 202461933
Apr 2024623524
May 202424119
Jun 20245258
Jul 202452217
Aug 202453613
Sep 20243318
Oct 2024132222
Nov 20248249
Dec 202461810
Jan 202503420
Feb 202547610
Mar 202594418
Apr 202545045
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (9)
Journal of Nuclear Medicine
Vol. 60, Issue 9
September 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients
Else A. Aalbersberg, Daphne M.V. Huizing, Iris Walraven, Berlinda J. de Wit-van der Veen, Harshad R. Kulkarni, Aviral Singh, Marcel P.M. Stokkel, Richard P. Baum
Journal of Nuclear Medicine Sep 2019, 60 (9) 1259-1265; DOI: 10.2967/jnumed.118.224386

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients
Else A. Aalbersberg, Daphne M.V. Huizing, Iris Walraven, Berlinda J. de Wit-van der Veen, Harshad R. Kulkarni, Aviral Singh, Marcel P.M. Stokkel, Richard P. Baum
Journal of Nuclear Medicine Sep 2019, 60 (9) 1259-1265; DOI: 10.2967/jnumed.118.224386
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • KEY POINTS
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Clinical

  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
  • SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
  • Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
Show more Clinical

Similar Articles

Keywords

  • PRRT
  • neuroendocrine tumor
  • multivariate analysis
SNMMI

© 2025 SNMMI

Powered by HighWire